NCT06548607View on ClinicalTrials.gov

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 14, 2024

Primary Completion Date

July 29, 2026

Study Completion Date

July 29, 2027

Conditions
SLE (Systemic Lupus)Systemic SclerosisANCA Associated VasculitisIdiopathic Inflammatory MyopathiesSjogren's SyndromeAutoimmune Diseases
Interventions
DRUG

RD06-04 or RD06-05 CART Cell Injection

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Trial Locations (1)

233000

RECRUITING

The Third the People's Hospital of Bengbu, Bengbu

All Listed Sponsors
lead

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY